Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Introduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended
after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable …

Background: Multiple published quantitative systematic reviews have reported on adverse
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …

Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety
profile based on data obtained from numerous clinical trials, including cardiovascular …

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy during women's
reproductive age. PCOS is a heterogeneous disorder featuring specific cardiometabolic …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) are a recent class of
medication approved for the treatment of type 2 diabetes (T2D). Previous meta-analyses …

Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the
urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease …

Abstract Objectives Sodium-glucose cotransporter-2 (SGLT2) inhibitor–induced glycosuria is
hypothesized to increase the risk of urinary tract infections (UTIs). We assessed the risk of …

Introduction The sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin is approved
for the treatment of adults with type 2 diabetes mellitus (T2DM). This analysis was conducted …

Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the
single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration …